NCT04591301View on ClinicalTrials.gov

The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

July 4, 2019

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

HEC113995 PA•H2O tablets

Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

DRUG

Placebo tablets

Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04591301 - The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter